Cargando…
Transition of clinical and basic studies on liver cirrhosis treatment using cells to seek the best treatment
The liver is a highly regenerative organ; however, its regeneration potential is reduced by chronic inflammation with fibrosis accumulation, leading to cirrhosis. With an aim to tackle liver cirrhosis, a life-threatening disease, trials of autologous bone marrow cell infusion (ABMi) therapy started...
Autores principales: | Terai, Shuji, Tsuchiya, Atsunori, Watanabe, Yusuke, Takeuchi, Suguru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444392/ https://www.ncbi.nlm.nih.gov/pubmed/34530931 http://dx.doi.org/10.1186/s41232-021-00178-3 |
Ejemplares similares
-
Mesenchymal stem cell therapies for liver cirrhosis: MSCs as “conducting cells” for improvement of liver fibrosis and regeneration
por: Tsuchiya, Atsunori, et al.
Publicado: (2019) -
Diverse perspectives to address for the future treatment of heterogeneous hepatocellular carcinoma
por: Tsuchiya, Atsunori, et al.
Publicado: (2019) -
Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
por: Sakamaki, Akira, et al.
Publicado: (2017) -
Prognostic study of acute-on-chronic liver failure patients: Usefulness of the fibrosis-4 index
por: Watanabe, Yusuke, et al.
Publicado: (2022) -
Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases
por: Tsuchiya, Atsunori, et al.
Publicado: (2017)